Clinical Trial Update: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Eloralintide (LY3841136) for persistent obesity treated with a weekly incretin, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Eloralintide (LY3841136)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Overweight, Obesity | Phase 3 | Status: RECRUITING